The companies are working on shots against pathogens that can cause long-term health issues
Craig F. Walker/Globe Staff
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Eli Lilly said Tuesday it would buy three early- and mid-stage vaccine developers, a boost for the field.
The deals — which together could cost up to nearly $4 billion — are the latest acquisitions from Lilly, a company rich with cash from its booming GLP-1 business. In recent months, it’s picked up companies working on cancer, autoimmune diseases, and sleep disorders, all for under $10 billion each.
